Nature Communications (Jun 2020)
Synergism between IL7R and CXCR4 drives BCR-ABL induced transformation in Philadelphia chromosome-positive acute lymphoblastic leukemia
- Hend Abdelrasoul,
- Anila Vadakumchery,
- Markus Werner,
- Lennart Lenk,
- Ahmad Khadour,
- Marc Young,
- Omar El Ayoubi,
- Fotini Vogiatzi,
- Markus Krämer,
- Vera Schmid,
- Zhengshan Chen,
- Yasar Yousafzai,
- Gunnar Cario,
- Martin Schrappe,
- Markus Müschen,
- Christina Halsey,
- Medhanie A. Mulaw,
- Denis M. Schewe,
- Elias Hobeika,
- Ameera Alsadeq,
- Hassan Jumaa
Affiliations
- Hend Abdelrasoul
- Institute of Immunology, Ulm University Medical Center
- Anila Vadakumchery
- Institute of Immunology, Ulm University Medical Center
- Markus Werner
- Institute of Immunology, Ulm University Medical Center
- Lennart Lenk
- Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein
- Ahmad Khadour
- Institute of Immunology, Ulm University Medical Center
- Marc Young
- Institute of Immunology, Ulm University Medical Center
- Omar El Ayoubi
- Institute of Immunology, Ulm University Medical Center
- Fotini Vogiatzi
- Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein
- Markus Krämer
- Institute of Immunology, Ulm University Medical Center
- Vera Schmid
- Institute of Immunology, Ulm University Medical Center
- Zhengshan Chen
- Department of Systems Biology and City of Hope Comprehensive Cancer Center
- Yasar Yousafzai
- Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow
- Gunnar Cario
- Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein
- Martin Schrappe
- Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein
- Markus Müschen
- Department of Systems Biology and City of Hope Comprehensive Cancer Center
- Christina Halsey
- Institute of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow
- Medhanie A. Mulaw
- Institute of Experimental Cancer Research, Medical Faculty, University of Ulm
- Denis M. Schewe
- Department of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein
- Elias Hobeika
- Institute of Immunology, Ulm University Medical Center
- Ameera Alsadeq
- Institute of Immunology, Ulm University Medical Center
- Hassan Jumaa
- Institute of Immunology, Ulm University Medical Center
- DOI
- https://doi.org/10.1038/s41467-020-16927-w
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 12
Abstract
Emergence of ABL1 kinase inhibitor resistant clones may cause disease relapse in Philadelphia chromosome-positive acute lymphoblastic leukemia. Here, the authors show interleukin 7 receptor (IL7R) signaling to contribute to this resistance mechanism, and that targeting the IL7R pathway may suppress incurable drug-resistant leukemia forms.
